2022 Translational Research Grants Funded
In 2022, we supported three flagship Translational Program Grants, awarded to teams led by Professor Philip Hogg, Professor Glenn Marshall and Dr James Wilmott, with a total investment of more than $11 million.
Professor Hogg is leading a world-first research program in theranostics – promising a new wave of cancer treatment.
Professor Marshall is aiming to give adolescent and young adults with sarcoma access to better diagnostic tests, therapy, and supportive care to strengthen cancer survivorship.
Dr Wilmott is developing a new, personalised approach to the use of immunotherapies which could radically change the way cancer treatments are selected for people with advanced cancers.
2022 Grant Recipients and Details
Grantee: Professor Philip Hogg
Administering Institution: Centenary Institute of Cancer Medicine and Cell Biology
Grant Title: Clinical development of a self-amplifying pan-tumour theranostic
Funding (excl. GST): $3,694,716
Grantee: Professor Glenn Marshall
Administering Institution: University of New South Wales
Project: Improving outcomes for children and young adults with sarcoma
Funding (excl. GST): $3,748,894
Grantee: Professor James Wilmott
Administering Institution: University of Sydney
Grant Title: Personalised Immunotherapy Program – Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform
Funding (excl. GST): $3,748,551